The estimated Net Worth of Michael York is at least $51.1 ezer dollars as of 26 January 2023. Mr. York owns over 107,054 units of PhaseBio Pharmaceuticals stock worth over $7,255 and over the last 6 years he sold PHAS stock worth over $43,892. In addition, he makes $0 as Vice President - Corporate Development and Commercial Strategy at PhaseBio Pharmaceuticals.
Michael has made over 1 trades of the PhaseBio Pharmaceuticals stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 107,054 units of PHAS stock worth $43,892 on 26 January 2023.
The largest trade he's ever made was selling 107,054 units of PhaseBio Pharmaceuticals stock on 26 January 2023 worth over $43,892. On average, Michael trades about 15,293 units every 0 days since 2019. As of 26 January 2023 he still owns at least 103,499 units of PhaseBio Pharmaceuticals stock.
You can see the complete history of Mr. York stock trades at the bottom of the page.
Michael B. York serves as Vice President - Corporate Development and Commercial Strategy of the Company. Prior to joining our company, Mr. York served as the vice president of global business development and alliance management of Orexigen Therapeutics, Inc. from August 2015 to June 2018. He previously served as a senior advisor for MKO Global Partners, L.P. from January 2015 to August 2015. Mr. York received a B.A. in public administration and economics from San Diego State University and an M.B.A. from the University of Redlands.
Michael York is 55, he's been the Vice President - Corporate Development and Commercial Strategy of PhaseBio Pharmaceuticals since 2018. There are 7 older and 9 younger executives at PhaseBio Pharmaceuticals. The oldest executive at PhaseBio Pharmaceuticals, Inc. is Nancy Hutson, 70, who is the Independent Director.
Michael's mailing address filed with the SEC is C/O METACRINE, INC., 4225 EXECUTIVE SQUARE, SUITE 600, SAN DIEGO, CA, 92037.
Over the last 6 years, insiders at PhaseBio Pharmaceuticals have traded over $361,083 worth of PhaseBio Pharmaceuticals stock and bought 24,000 units worth $81,960 . The most active insiders traders include Clay Thorp, Enterprise Associates 13 Lp... és Nancy J Hutson. On average, PhaseBio Pharmaceuticals executives and independent directors trade stock every 52 days with the average trade being worth of $5,138. The most recent stock trade was executed by Clay Thorp on 19 May 2023, trading 3,750 units of PHAS stock currently worth $263.
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.
PhaseBio Pharmaceuticals executives and other stock owners filed with the SEC include: